Investors Buy Merck & Company, Inc. (MRK) on Weakness
Investors purchased shares of Merck & Company, Inc. (NYSE:MRK) on weakness during trading hours on Friday. $129.72 million flowed into the stock on the tick-up and $48.10 million flowed out of the stock on the tick-down, for a money net flow of $81.62 million into the stock. Of all equities tracked, Merck & had the 4th highest net in-flow for the day. Merck & traded down ($0.05) for the day and closed at $64.27
Several research firms have commented on MRK. HSBC Holdings plc raised shares of Merck & from a “reduce” rating to a “hold” rating in a report on Wednesday, August 9th. BidaskClub lowered shares of Merck & from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. UBS AG upped their price target on shares of Merck & from $70.00 to $72.00 and gave the company a “buy” rating in a report on Monday, July 31st. Credit Suisse Group reaffirmed an “outperform” rating and issued a $74.00 price target (down from $75.00) on shares of Merck & in a report on Tuesday. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $74.00 price target on shares of Merck & in a report on Tuesday, June 6th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $69.68.
The firm has a 50-day moving average of $62.94 and a 200-day moving average of $63.72. The company has a market capitalization of $175.29 billion, a PE ratio of 34.80 and a beta of 0.81.
Merck & (NYSE:MRK) last released its quarterly earnings data on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $0.14. The firm had revenue of $9.93 billion for the quarter, compared to the consensus estimate of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The firm’s revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.93 earnings per share. Analysts forecast that Merck & Company, Inc. will post $3.88 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Investors of record on Friday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 2.93%. The ex-dividend date is Thursday, September 14th. Merck &’s dividend payout ratio is currently 76.11%.
Hedge funds have recently added to or reduced their stakes in the stock. Stelac Advisory Services LLC acquired a new position in Merck & during the second quarter worth about $104,000. Perennial Advisors LLC raised its position in Merck & by 10.7% during the second quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock worth $104,000 after acquiring an additional 157 shares during the last quarter. Cascade Investment Advisors Inc. raised its position in Merck & by 15.5% during the second quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock worth $111,000 after acquiring an additional 232 shares during the last quarter. Vigilant Capital Management LLC raised its position in Merck & by 16.7% during the first quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock worth $111,000 after acquiring an additional 250 shares during the last quarter. Finally, Solaris Asset Management LLC raised its position in Merck & by 6.3% during the second quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock worth $124,000 after acquiring an additional 115 shares during the last quarter. 73.02% of the stock is currently owned by hedge funds and other institutional investors.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.